119 related articles for article (PubMed ID: 33851736)
21. Human Papillomavirus in Thai Women and Men with Anogenital Warts.
Nilyanimit P; Chansaenroj J; Srisomboon J; Rodrangnok W; Rajakom N; Daengsaard E; Sookrak N; Poovorawan Y
Intervirology; 2018; 61(5):223-229. PubMed ID: 30904912
[TBL] [Abstract][Full Text] [Related]
22. Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes.
Mesher D; Soldan K; Lehtinen M; Beddows S; Brisson M; Brotherton JM; Chow EP; Cummings T; Drolet M; Fairley CK; Garland SM; Kahn JA; Kavanagh K; Markowitz L; Pollock KG; Söderlund-Strand A; Sonnenberg P; Tabrizi SN; Tanton C; Unger E; Thomas SL
Emerg Infect Dis; 2016 Oct; 22(10):1732-40. PubMed ID: 27648688
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of HPV genotypes determined by PCR and DNA sequencing in cervical specimens from French women with or without abnormalities.
Pannier-Stockman C; Segard C; Bennamar S; Gondry J; Boulanger JC; Sevestre H; Castelain S; Duverlie G
J Clin Virol; 2008 Aug; 42(4):353-60. PubMed ID: 18485810
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of carcinogenic human papillomavirus infection in Suzhou: Epidemiology, vaccine evaluation, and associated diseases.
Li WJ; Xu HX; Chen ZH; Xu WD; Wu YJ
J Med Virol; 2017 May; 89(5):895-901. PubMed ID: 27696465
[TBL] [Abstract][Full Text] [Related]
25. HPV genotype prevalence in Indian women with cervical disease and estimation of the potential impact of HPV vaccines on prevention of cervical cancer.
Nagaraja M; Narendra H; Venkataramana B; Kalawat U
Indian J Med Microbiol; 2023; 43():73-78. PubMed ID: 36241529
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus prevalence and distribution in self-collected samples from female university students in Maputo.
Bule YP; Silva J; Carrilho C; Campos C; Sousa H; Tavares A; Medeiros R
Int J Gynaecol Obstet; 2020 May; 149(2):237-246. PubMed ID: 32086940
[TBL] [Abstract][Full Text] [Related]
27. Racial/ethnic variation in the prevalence of vaccine-related human papillomavirus genotypes.
Montealegre JR; Varier I; Bracamontes CG; Dillon LM; Guillaud M; Sikora AG; Follen M; Adler-Storthz K; Scheurer ME
Ethn Health; 2019 Oct; 24(7):804-815. PubMed ID: 28870103
[No Abstract] [Full Text] [Related]
28. Pre-vaccination prevalence of high-risk human papillomaviruses (HPV) in women from Kosovo and their related sociodemographic characteristics.
Zejnullahu Raçi P; Hošnjak L; Poljak M; Lepej SŽ; Vince A
Ginekol Pol; 2018; 89(9):485-494. PubMed ID: 30318575
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and Risk Factors of Human Papillomavirus Infection in 18-Year-Old Women: Baseline Report of a Prospective Study on Human Papillomavirus Vaccine.
Igidbashian S; Boveri S; Bottari F; Vidal Urbinati A; Preti E; Casadio C; Landoni F; Sideri M; Sandri MT
J Low Genit Tract Dis; 2017 Jan; 21(1):4-8. PubMed ID: 27755229
[TBL] [Abstract][Full Text] [Related]
30. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of human papillomavirus genotypes in northern Taiwanese women.
Tsao KC; Huang CG; Kuo YB; Chang TC; Sun CF; Chang CA; Yang SL; Chan EC
J Med Virol; 2010 Oct; 82(10):1739-45. PubMed ID: 20827772
[TBL] [Abstract][Full Text] [Related]
32. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
33. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
[TBL] [Abstract][Full Text] [Related]
34. Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis.
Bissett SL; Godi A; Jit M; Beddows S
Vaccine; 2017 Jul; 35(32):3922-3929. PubMed ID: 28633892
[TBL] [Abstract][Full Text] [Related]
35. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.
Godi A; Kemp TJ; Pinto LA; Beddows S
J Infect Dis; 2019 Nov; 220(12):1940-1945. PubMed ID: 31412122
[TBL] [Abstract][Full Text] [Related]
36. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
Schiller JT; Castellsagué X; Villa LL; Hildesheim A
Vaccine; 2008 Aug; 26 Suppl 10(Suppl 10):K53-61. PubMed ID: 18847557
[TBL] [Abstract][Full Text] [Related]
37. Genotypic distribution of human oncogenic papillomaviruses in sexually active women in Burkina Faso: Central, Central-Eastern and Hauts-Bassins regions.
Ouedraogo RA; Zohoncon TM; Traore IMA; Ouattara AK; Guigma SP; Djigma FW; Obiri-Yeboah D; Ouedraogo C; Simpore J
Biomol Concepts; 2020 May; 11(1):125-136. PubMed ID: 32417758
[TBL] [Abstract][Full Text] [Related]
38. Human Papillomavirus (HPV) Genotyping Assay Suitable for Monitoring the Impact of the 9-Valent HPV Vaccine.
Kukimoto I; Matsumoto K; Takahashi F; Iwata T; Tanaka K; Yamaguchi-Naka M; Yamamoto K; Yahata H; Nakabayashi M; Kato H; Tsuda N; Onuki M; Yaegashi N;
Tohoku J Exp Med; 2020 Aug; 251(4):287-294. PubMed ID: 32759554
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus genotype distribution in invasive cervical cancer in Bosnia and Herzegovina.
Iljazović E; Mena M; Tous S; Alemany L; Omeragić F; Sadiković A; Clavero O; Vergara M; Bosch FX; de Sanjosé S
Cancer Epidemiol; 2014 Oct; 38(5):504-10. PubMed ID: 25130915
[TBL] [Abstract][Full Text] [Related]
40. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.
Struyf F; Colau B; Wheeler CM; Naud P; Garland S; Quint W; Chow SN; Salmerón J; Lehtinen M; Del Rosario-Raymundo MR; Paavonen J; Teixeira JC; Germar MJ; Peters K; Skinner SR; Limson G; Castellsagué X; Poppe WA; Ramjattan B; Klein TD; Schwarz TF; Chatterjee A; Tjalma WA; Diaz-Mitoma F; Lewis DJ; Harper DM; Molijn A; van Doorn LJ; David MP; Dubin G;
Clin Vaccine Immunol; 2015 Feb; 22(2):235-44. PubMed ID: 25540273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
